Bohden Yaremko

Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.

W. R. Bishop, Meilin Liu, L. Nielsen, 1999, Cancer research.

Inhibition of Angiogenesis and Tumor Growth by SCH221153, a Dual αvβ3 and αvβ5 Integrin Receptor Antagonist

B. Neustadt, L. Armstrong, C. Kumar, 2001 .